Park 2017.

Study characteristics
Methods	Double‐blind placebo‐controlled pilot study
Participants	Diagnosis: DSM‐IV Bipolar disorder, MADRS score ≥20 N: riluzole N=8, placebo N=11 Age: Riluzole group: 45.25 (SD = 15.46) Placebo group: 47.64 (SD = 11.11) Sex: riluzole group: 7 males, 1 female Placebo group: 6 males, 5 females Baseline depression severity: data unavailable
Interventions	Participants were tapered off of any medications and were free of medications with central nervous system effects for seven days prior to the study and throughout the study, except for lorazepam as needed (up to 2 mg/day to manage agitation or anxiety). Riluzole (50 mg to 200mg/day) or placebo for eight weeks administered orally. Riluzole dosing began at 50 mg, twice daily, and was increased on a weekly basis by 50 mg, as tolerated, up to a maximum dose of 200 mg/day.
Outcomes	Dropout rate
Notes	Trial ended prematurely due to futility. Limited data available.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote:"Randomized in a 1:1 allocation"
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No details given.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No details given.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Not significant.
Selective reporting (reporting bias)	High risk	Data from many outcomes not published.
Other bias	Unclear risk	None detected.